Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00375076

Enrollment

Unknown

Registered

2006-09-12

Start date

2006-06-30

Completion date

2008-05-31

Last updated

2009-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.

Interventions

DRUGenoxaparin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients (\> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH: * Immobilization * History of VTE * Acute inflammation * Heart failure (NYHA class III or IV) * Respiratory failure

Exclusion criteria

* Indication for LMWH or UFH at therapeutic dosages * Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction) * Contraindication for the treatment with LMWH * Major surgery within the last 4 weeks; minor surgery within the last week * Thrombocytopenia (\< 100.000/μl) * Prolonged prothrombin time * Prolonged activated partial thromboplastin time (aPTT) * History of heparin-induced thrombocytopenia * Bodyweight \< 50 kg or \> 100 kg * Renal insufficiency (creatinine \> 2 mg/dl)

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026